ATE334120T1 - Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems - Google Patents
Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystemsInfo
- Publication number
- ATE334120T1 ATE334120T1 AT95944268T AT95944268T ATE334120T1 AT E334120 T1 ATE334120 T1 AT E334120T1 AT 95944268 T AT95944268 T AT 95944268T AT 95944268 T AT95944268 T AT 95944268T AT E334120 T1 ATE334120 T1 AT E334120T1
- Authority
- AT
- Austria
- Prior art keywords
- amine
- butene
- methyl
- nervous system
- central nervous
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- HXZOBONAESLRFT-HNQUOIGGSA-N (e)-4-pyrimidin-5-ylbut-3-en-1-amine Chemical compound NCC\C=C\C1=CN=CN=C1 HXZOBONAESLRFT-HNQUOIGGSA-N 0.000 abstract 1
- XBTZRFSIPNDBPJ-DUXPYHPUSA-N (e)-n-methyl-4-pyrimidin-5-ylbut-3-en-1-amine Chemical compound CNCC\C=C\C1=CN=CN=C1 XBTZRFSIPNDBPJ-DUXPYHPUSA-N 0.000 abstract 1
- JUOSGGQXEBBCJB-DJWKRKHSSA-N (z)-n-methyl-4-pyridin-3-ylbut-3-en-1-amine Chemical compound CNCC\C=C/C1=CC=CN=C1 JUOSGGQXEBBCJB-DJWKRKHSSA-N 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 150000007824 aliphatic compounds Chemical class 0.000 abstract 1
- -1 amine compound Chemical group 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- NFZVCHHDNNTURD-UHFFFAOYSA-N n-methyl-1-pyridin-3-ylbutan-1-amine Chemical compound CCCC(NC)C1=CC=CN=C1 NFZVCHHDNNTURD-UHFFFAOYSA-N 0.000 abstract 1
- WBAIXNUCEGCLDC-UHFFFAOYSA-N n-methyl-4-pyridin-3-ylbut-3-yn-1-amine Chemical compound CNCCC#CC1=CC=CN=C1 WBAIXNUCEGCLDC-UHFFFAOYSA-N 0.000 abstract 1
- JUOSGGQXEBBCJB-GORDUTHDSA-N rivanicline Chemical compound CNCC\C=C\C1=CC=CN=C1 JUOSGGQXEBBCJB-GORDUTHDSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/364,977 US5824692A (en) | 1995-01-06 | 1995-01-06 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US08/364,979 US5597919A (en) | 1995-01-06 | 1995-01-06 | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US08/364,978 US5731314A (en) | 1995-01-06 | 1995-01-06 | Pharamceutical compositions for prevention and treatment of tourette's syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334120T1 true ATE334120T1 (de) | 2006-08-15 |
Family
ID=27408680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95944268T ATE334120T1 (de) | 1995-01-06 | 1995-12-28 | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0801527B1 (de) |
| JP (1) | JP3899126B2 (de) |
| AT (1) | ATE334120T1 (de) |
| AU (1) | AU4610896A (de) |
| DE (1) | DE69535131T2 (de) |
| WO (1) | WO1996020600A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| ES2318856T4 (es) | 1996-04-23 | 2010-03-03 | Targacept, Inc. | Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central. |
| US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5811442A (en) * | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| US6531606B1 (en) | 1997-02-21 | 2003-03-11 | Targacept, Inc. | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| CA2281564A1 (en) * | 1997-02-21 | 1998-08-27 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
| JP4240815B2 (ja) * | 1998-06-16 | 2009-03-18 | ターガセプト，インコーポレイテッド | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US20050131034A1 (en) | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
| EP1185514A1 (de) * | 1999-06-07 | 2002-03-13 | Targacept, Inc. | Pharmaceutische zusammensetzungen und verwendungsmethode |
| JP4815083B2 (ja) * | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
| AU2001257449A1 (en) * | 2000-05-01 | 2001-11-12 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
| US6743812B1 (en) * | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE62662B1 (en) * | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
| US5212188A (en) * | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
-
1995
- 1995-12-28 EP EP95944268A patent/EP0801527B1/de not_active Expired - Lifetime
- 1995-12-28 AT AT95944268T patent/ATE334120T1/de not_active IP Right Cessation
- 1995-12-28 WO PCT/US1995/017034 patent/WO1996020600A1/en not_active Ceased
- 1995-12-28 DE DE69535131T patent/DE69535131T2/de not_active Expired - Fee Related
- 1995-12-28 AU AU46108/96A patent/AU4610896A/en not_active Abandoned
- 1995-12-28 JP JP52117196A patent/JP3899126B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996020600A1 (en) | 1996-07-11 |
| JP3899126B2 (ja) | 2007-03-28 |
| DE69535131D1 (de) | 2006-09-07 |
| EP0801527A1 (de) | 1997-10-22 |
| JP2001520628A (ja) | 2001-10-30 |
| EP0801527A4 (de) | 2001-09-05 |
| DE69535131T2 (de) | 2007-03-01 |
| AU4610896A (en) | 1996-07-24 |
| EP0801527B1 (de) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE334120T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems | |
| ATE261244T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis | |
| DE69739142D1 (de) | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen | |
| DE602004030222D1 (de) | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen | |
| ATE302194T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
| NO961326D0 (no) | Inhibitorer av | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE69906671D1 (de) | Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE69313267D1 (en) | 1-alkoxy-2-(alkoxy oder cycloalkoxy)-4-(cyclothioalkyl- oder cyclothioalkenyl)benzole als inhibitoren von cyclischen amp phosphodiesterase und tumornekrosefaktor | |
| WO2003104217A3 (en) | AMINO ACID PROMOTERS EXCITATORS | |
| DE69413829D1 (de) | Antiglucocorticoidsteroide zur behandlung von angststörungen | |
| IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE274496T1 (de) | Pharmazeutische zusammensetzungen welche aryl- substituierte olefinische amin-verbindungen enthalten | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| ATE172118T1 (de) | Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose | |
| DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| ATE168697T1 (de) | Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen | |
| DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
| ATE242766T1 (de) | Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |